Sept. 3, 2020: A hepatitis C microelimination program for people living with HIV; PrEP concentrations and gender-affirming hormones; a collaborative intervention to improve opioid prescribing practices; TDF and fracture risk.
With Several Curative Therapies for Hepatitis C on the Market, the Research Pipeline for Prevention Continues
The authors of an influential annual report on hepatitis C research and development talk through what's new and evolving in clinical science.
Aug. 13, 2020: HCV testing rates among people newly diagnosed with HIV; HCV treatment referrals ammong coinfected people; HIV mortality rates despite free treatment access; mysterious, plummeting CD4 test results.
An interview with Andrew Hill, Ph.D., about his research presented at AIDS 2020.
July 23, 2020: Depression and HIV risk mitigation among MSM; a consistent HIV provider is good for CD4 and viral load; spirituality and HIV prevention; HCV treatment access and reinfection risk.
July 9, 2020: Abysmal HIV testing rates in U.S. ambulatory care settings; STI testing frequency in PrEP users; trends in U.S. PrEP uptake; integrating opioid therapy with HCV care in people who inject drugs.
A revolution in organ transplants is taking place.
Will We Ever Have a Hepatitis C Vaccine? Two Activists Weigh in on the Challenges and Opportunities Ahead
A new injection of funding from Congress could be the catalyst for a future hepatitis C (HCV) vaccine.
June 4, 2020: The latest on COVID-19 hospitalization among people with HIV; real-world success of hepatitis C treatment in coinfected patients with good health care; poverty and adherence in Canada's health system; demographic and socioeconomic factors associated with viral rebound.
May 7, 2020: Epidemiological factors among transgender women; revised PrEP indication estimates for MSM; trends in HIV strain similarity between younger and older MSM; current hepatitis C epidemic among British MSM with HIV.